About: Immune-Related Adverse Events: Pneumonitis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immune-Related Adverse Events: Pneumonitis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immune-Related Adverse Events: Pneumonitis
Creator	Sheshadri, Ajay Zhong, Linda Shannon, Vickie Altan, Mehmet
Source	PMC
abstract	Checkpoint inhibitors are part of the family of immunotherapies and are increasingly being used in a wide variety of cancers. Immune-related adverse events pose a major challenge in the treatment of cancer patients. Pneumonitis is a rare immune-related adverse event that presents in distinct patterns. The goal of this chapter is to instruct readers on the incidence and clinical manifestations of pneumonitis and to offer guidance in the evaluation and treatment of patients with pneumonitis.
has issue date	2020-04-17(xsd:dateTime)
bibo:doi	10.1007/978-3-030-41008-7_13
bibo:pmid	32301020
has license	no-cc
sha1sum (hex)	dc55465b1307fb8ce2d070c088aecfedb7dcd2e7
schema:url	https://doi.org/10.1007/978-3-030-41008-7_13
resource representing a document's title	Immune-Related Adverse Events: Pneumonitis
has PubMed Central identifier	PMC7161534
has PubMed identifier	32301020
schema:publication	Immunotherapy
resource representing a document's body	covid:dc55465b1307fb8ce2d070c088aecfedb7dcd2e7#body_text
is schema:about of	named entity 'The goal' named entity 'rare' named entity 'cancers' named entity 'readers' named entity 'GOAL' named entity 'FAMILY' named entity 'CANCERS' named entity 'PATIENTS' named entity 'VARIETY' named entity 'INHIBITORS' named entity 'PD-L1' named entity 'pneumonitis' named entity 'pneumonitis' named entity 'autoimmune diseases' named entity 'PD-1' named entity 'ipilimumab' named entity 'congestive heart failure' named entity 'pneumonitis' named entity 'cytokine' named entity 'antitumor' named entity 'pneumonitis' named entity 'secretion' named entity 'pulmonary function testing' named entity 'high-grade' named entity 'inflammatory bowel disease' named entity 'pleural' named entity 'infection' named entity 'distal' named entity 'CTLA-4' named entity 'general population' named entity 'SHP2' named entity 'CTLA-4' named entity 'homolog' named entity 'dyspnea' named entity 'alveolar walls' named entity 'PD-L1' named entity 'phase II trials' named entity 'ICI' named entity 'CTLA-4' named entity 'control patients' named entity 'pneumonitis' named entity 'Pneumonitis' named entity 'stage III' named entity 'Bronchoalveolar lavage' named entity 'rechallenge' named entity 'atezolizumab' named entity 'pembrolizumab' named entity 'prospective study' named entity 'pneumonitis' named entity 'ipilimumab' named entity 'pneumonitis' named entity 'dendritic cells' named entity 'adverse event' named entity 'patients' named entity 'patterns' named entity 'inhibitors' named entity 'PD-1' named entity 'inflammatory cell' named entity 'DAD' named entity 'immunotherapy' named entity 'B7-2' named entity 'pneumocyte' named entity 'PD-1' named entity 'pneumonitis' named entity 'PD-1 inhibitors' named entity 'PD-1 inhibitors' named entity 'CTLA-4' named entity 'reverse halo sign' named entity 'ICI' named entity 'CTLA-4' named entity 'CTLA-4' named entity 'histology' named entity 'refractory' named entity 'ipilimumab' named entity 'edema' named entity 'pneumonitis' named entity 'case series' named entity 'rechallenge'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software